Skip to main content
LUYAN PHARMA CO.,LTD logo

LUYAN PHARMA CO.,LTD — Investor Relations & Filings

Ticker · 002788 ISIN · CNE1000025W1 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2018-04-23 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002788

About LUYAN PHARMA CO.,LTD

https://www.luyan.com.cn

Luyan Pharma Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive logistics network, providing supply chain management services to healthcare institutions, including hospitals and community clinics. Its product portfolio encompasses a wide range of Western pharmaceuticals, traditional Chinese medicines, and medical equipment. In addition to wholesale distribution, the company maintains a significant presence in the retail pharmacy sector through a chain of drugstores. Luyan Pharma focuses on optimizing healthcare delivery through integrated distribution systems and value-added services, such as third-party logistics and pharmaceutical cold chain management. The organization leverages its regional market leadership to expand its service footprint and enhance the efficiency of the medical supply chain.

Recent filings

Filing Released Lang Actions
独立董事2017年度述职报告（郭小东）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2017 Annual Work Report" for a company, detailing the independent director's attendance at board and shareholder meetings, opinions on various company matters, committee roles, and efforts to protect minority shareholders' rights. It is a narrative report on the director's activities and responsibilities during the year 2017. The document is relatively short (2955 characters) and does not contain financial statements or detailed financial data. It is not an annual report, audit report, or financial supplement. It is a management-related report focusing on board activities and governance. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports on their duties.
2018-04-23 Chinese
第四届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the supervisory board (监事会) of 鹭燕医药股份有限公司 regarding the resolution of their third meeting of the fourth supervisory board. It discusses the approval of using idle raised funds temporarily to supplement working capital, including voting results and references to regulatory compliance and independent opinions. The document is short (1315 characters) and primarily serves as a meeting resolution announcement rather than a detailed financial report or audit. It does not contain financial statements or detailed financial analysis. It is not an annual or interim report, nor an earnings release. It is not a proxy solicitation or voting results declaration. The content fits best with a regulatory announcement about a board/supervisory meeting decision related to capital use. Given the nature of the supervisory board meeting resolution and the announcement of decisions, the best fitting category is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other more specific categories.
2018-04-12 Chinese
国信证券股份有限公司关于公司使用部分闲置募集资金暂时补充流动资金的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a special investigation opinion by the sponsor Guosen Securities regarding the use of part of idle raised funds by Luyan Pharmaceutical Co., Ltd. It references regulatory guidelines on the management and use of raised funds, details the amount and usage of the funds, and confirms compliance with relevant rules. The document is a verification or audit opinion on the use of raised funds, not a full annual or interim report, nor an announcement of voting results or capital changes. It is a standalone audit-related report focusing on the use of funds raised in an IPO, which fits the category of Audit Report / Information (AR). The document length is 2231 characters, which is short but contains substantive content, not just an announcement or certification letter. Therefore, it is classified as AR with high confidence.
2018-04-12 Chinese
独立董事关于使用部分闲置募集资金暂时补充流动资金的独立意见
Regulatory Filings Classification · 95% confidence The document is a formal independent opinion from the independent directors of 鹭燕医药股份有限公司 regarding the company's use of part of its idle raised funds to temporarily supplement working capital. It references compliance with stock exchange listing rules and internal fundraising management systems. The document is short (1222 characters), contains no financial statements or detailed financial data, and is essentially a certification or attestation by independent directors on a specific corporate action related to fundraising use. It does not present a full audit report, annual report, or financial results. Given these characteristics and the nature of the document as an independent opinion or certification, it fits best under Regulatory Filings (RNS) rather than Audit Report or Capital/Financing Update, as it is not a financing announcement but a formal opinion on fund usage compliance.
2018-04-12 Chinese
关于使用部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 鹭燕医药股份有限公司 regarding the use of part of idle raised funds to temporarily supplement working capital. It details the amount of funds raised, previous approvals, usage plans, and compliance with regulatory requirements. The document includes opinions from the board, independent directors, supervisors, and the sponsoring institution. It does not contain financial statements or detailed financial performance data but rather focuses on the company's capital usage plan and regulatory compliance. The document length is 4177 characters, which is relatively short and consistent with an announcement rather than a full report. The content aligns with updates on company fundraising and capital structure usage rather than a full financial report or earnings release. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2018-04-12 Chinese
第四届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the fourth meeting of the fourth board of directors of 鹭燕医药股份有限公司. It details the meeting's convening, attendance, and the approval of a proposal regarding the temporary use of idle raised funds to supplement working capital. It references related documents and independent opinions but does not contain financial statements or detailed financial data. The document is an official announcement of board decisions rather than a full management report or financial report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2018-04-12 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.